Sofpironium

Brand names: Sofdra · Active ingredient: Sofpironium Bromide

In short: SOFDRA is indicated for the treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older.

Forms & strengthsTopical gel: 12.45% (w/w) of sofpironium in a 50 mL bottle with a metered dose pump and applicator. One full pump delivers 72 mg sofpironium in 0.67 mL of gel.
LabelBotanix SB Inc.
Label updatedSep 25, 2025

What is Sofpironium used for?

SOFDRA is indicated for the treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older.

Sofpironium dosage

Do not shave armpits at least 8 hours before applying SOFDRA.

Do not shower at least 30 minutes before applying SOFDRA.

Apply SOFDRA to clean, dry skin once a day at bedtime.

Apply a single pump actuation to the top of the supplied applicator. Spread the entire amount to cover 1 underarm. Apply a separate, single pump actuation to the top of the supplied applicator. Apply the entire amount to the second underarm. Allow to dry completely (5 minutes) before putting on clothing.

Wash hands immediately with soap.

For topical use only.

Avoid fire, flame, and smoking during and immediately following application.

Do not shower or wash underarms for at least 8 hours after application.

Do not touch underarms after applying SOFDRA.

Do not use more than once daily.

Avoid transfer of SOFDRA to the periocular area

.

Do not apply SOFDRA to broken skin.

Avoid using SOFDRA with occlusive dressings.

How to take Sofpironium — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

Urinary Retention

Instruct patients to be alert for signs and symptoms of urinary retention (e.g., difficulty passing urine, distended bladder). Instruct patients to discontinue use and consult a healthcare provider immediately should any of these signs or symptoms develop

.

Control of Body Temperature

Advise patients that in the presence of high ambient temperature, heat illness due to decreased sweating can occur with the use of SOFDRA. Advise patients to watch for generalized lack of sweating when in hot or very warm environmental temperatures and to avoid using SOFDRA if not sweating under these conditions

.

Operating Machinery or an Automobile

Advise patients that transient blurred vision may occur with SOFDRA. If this occurs, instruct patients to contact their healthcare provider, discontinue use of SOFDRA, and avoid operating a motor vehicle or other machinery or performing hazardous work until symptoms resolve

.

Instructions for Administering SOFDRA

Advise patients as follows

:

Do not shave armpits at least 8 hours before applying SOFDRA. …

Warnings & precautions

Do not take this medicine if: SOFDRA is contraindicated in patients with medical conditions that can be exacerbated by the anticholinergic effect of sofpironium bromide (e.g., glaucoma, paralytic ileus, unstable cardiovascular status in acute hemorrhage, severe ulcerative colitis, toxic megacolon complicating ulcerative colitis, myasthenia gravis, Sjögren's syndrome).

Use SOFDRA with caution in patients with a history or presence of documented urinary retention. Prescribers and patients should be alert for signs and symptoms of urinary retention (e.g., difficulty passing urine, distended bladder), especially in patients with prostatic hypertrophy or bladder-neck obstruction. Discontinue use immediately and consult a healthcare provider should any of these signs or symptoms develop.

In the presence of high ambient temperature, heat illness (hyperpyrexia and heat stroke due to decreased sweating) can occur with the use of anticholinergic drugs, including SOFDRA. Watch for generalized lack of sweating when in hot or very warm environmental temperatures and avoid using SOFDRA if not sweating under these conditions.

Transient blurred vision may occur with use of SOFDRA. If blurred vision occurs, discontinue use and avoid engaging in activities that require clear vision, such as operating a motor vehicle or other machinery or performing hazardous work, until the symptoms have resolved.

Sofpironium side effects

The following clinically significant adverse reactions are described elsewhere in the labeling:

Urinary Retention

.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In two double-blind, vehicle controlled clinical trials (CARDIGAN 1 and CARDIGAN 2) of 700 subjects 10 to 76 years of age (353 subjects treated with SOFDRA and 347 subjects treated with vehicle), 44% of subjects were male, 79% were White, 21% were Black, and 1% were Asian. A total of 618 subjects completed at least 6 weeks of treatment, including 307 subjects treated with SOFDRA and 311 subjects treated with vehicle.

Table 1 summarizes the most frequent adverse reactions (≥2%) in subjects with primary axillary hyperhidrosis treated with SOFDRA.

Adverse Reactions | SOFDRA

(N = 353)

n (%) | Vehicle

(N = 347)

n (%)

Note: COVID-19 was observed in 8 (2%) SOFDRA and 2 (0.6%) vehicle subjects.

Dry mouth | 51 (14%) | 2 (0.6%)

Vision blurred | 30 (9%) | 1 (0.3%)

Mydriasis | 23 (7%) | 0

Urinary retention | 8 (2%) | 0

Table 2 shows the local skin reactions reported ≥2%, which occurred more commonly in the SOFDRA group. …

Drug interactions

Coadministration of SOFDRA with anticholinergic medications may result in additive interaction leading to an increase in anticholinergic adverse effects

. Avoid coadministration of SOFDRA with other anticholinergic-containing drugs.

Avoid co-administration of SOFDRA with drugs that are strong inhibitors of CYP2D6.

About this medicine

SOFDRA (sofpironium) topical gel is an anticholinergic drug. Sofpironium bromide drug substance is a white to off white powder with the chemical name 3'(R)-[2(R) cyclopentylphenylhydroxy-acetoxy]-1'-methyl-1'-ethoxycarbonylmethyl-pyrrolidinium bromide, very soluble in chloroform and freely soluble in water, ethanol, acetonitrile, and methanol, molecular formula of C

22H

32BrNO

5, molecular weight of 470.4 g/mol, and the following structural formula:

SOFDRA is a clear to translucent, colorless to pale yellow viscous gel containing 12.45% (w/w) sofpironium (equivalent to 15% sofpironium bromide) in an airless bottle sealed with a multi-dose metered pump. Each pump delivers 72 mg of sofpironium (equivalent to 87 mg of sofpironium bromide) in 0.67 mL of gel. The inactive ingredients are citric acid, 77.2% v/v dehydrated alcohol, hexylene glycol, hydroxypropyl cellulose, and isopropyl myristate.

How it works: Sofpironium bromide is a competitive inhibitor of acetylcholine receptors that are located on certain peripheral tissues, including sweat glands. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 78f86f4f-658c-468b-bd54-49182ddcc7ac. Read the full official label on DailyMed.